%0 Journal Article
%T Immunosuppression Adjustment and Tumour Progress
%A R. Diller
%A H. Wolters
%A Ch. Weining
%A M. Seidel
%J Transplantationsmedizin
%D 2004
%I Pabst Science Publishers
%X In animal trials using sirolimus as an immunosuppressive agent, reduced tumour progression can be observed. As tumour development is increased during immunosuppression, treatment in immunosuppressed transplant patients is extremely difficult. During the past years, immunosuppressive regime was adjusted to sirolimus in 2 patients exhibiting advanced metastatic de novo tumour after transplantation (1 x CUP, 1 x prostatic) as well as in 2 patients who were retransplanted due to hepatic cell carcinoma (HCC) which was recurring later on. Furthermore, immunosuppression was gradually reduced in a female patient with advanced Kaposi¡¯s sarcoma, and after graft loss the transplanted kidney was removed. In total, further tumour progression at variable rate could be observed in all of the patients, only in the patient suffering from prostatic carcinoma treated by hormone-ablative therapy, temporary tumour regression was obserbed. In the two patients in whom palliative chemotherapy did not come into question, after diagnosis of hepatic cell carcinoma recurrence rapid tumour progression occurred in one of them and a more slower progression was seen in the other patient. Use of Sirolimus may lead to slowing of tumour growth by inhibition of VEGF. Single clinical observations, however, are not sufficient to support these findings.
%K tumour therapy
%K immunosuppression
%K hepatic cell carcinoma
%K transplantation
%K sirolimus
%U http://www.transplantation.de/fileadmin/transplantation/txmedizin/txmedizin_2004_2/Diller.pdf